Results 251 to 260 of about 2,487,415 (296)

Cisplatin Resistance Associated with PARP Hyperactivation

Cancer Research, 2013
Abstract Non–small cell lung carcinoma patients are frequently treated with cisplatin (CDDP), most often yielding temporary clinical responses. Here, we show that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin.
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D., Talbot, M., Robin, A., Girard, Pascal, Orear, C., Lissa, D., Sukkurwala, A., Garcia, P., Behnam-Motlagh, P., Kohno, K., Wu, G., Brenner, Catherine, Dessen, P., Saparbaev, M., Soria, J.-C., Castedo, M., Kroemer, G.   +25 more
openaire   +3 more sources

Resistance to cisplatin.

Anti-cancer drug design, 1999
Resistance to cis-diamminedichloroplatinum(II) (cisplatin), a DNA damaging agent, is a major obstacle for its clinical effectiveness. Multiple mechanisms may be involved in cisplatin resistance. Frequently cited mechanisms include reduced accumulation, elevated levels of glutathione (GSH) and metallothionein, and enhanced DNA repair.
S, Akiyama, Z S, Chen, T, Sumizawa, T, Furukawa   +3 more
openaire   +1 more source

Mechanisms of resistance to cisplatin and carboplatin

Critical Reviews in Oncology/Hematology, 2007
While cisplatin and carboplatin are active versus most common cancers, epithelial malignancies are incurable when metastatic. Even if an initial response occurs, acquired resistance due to mutations and epigenetic events limits efficacy. Resistance may be due to excess of a resistance factor, to saturation of factors required for tumor cell killing, or
openaire   +2 more sources

Resistance to cisplatin: How to deal with the problem?

European Journal of Cancer and Clinical Oncology, 1990
SINCE its introduction in clinical practice, cisplatin [cis-diamminedichloroplatinum( II), CDDP] has become one of the most important drugs for treating solid tumors. CDDP-based chemotherapy has clearly improved the response rate for treatment of testicular, ovarian and small cell lung tumors.
J L, Canon, Y, Humblet, M, Symann
openaire   +2 more sources

IN VITRO MODULATION OF CISPLATIN RESISTANCE BY CYTOKINES

Cytokine, 1999
We have previously demonstrated that treatment of wild-type (wt) T98G malignant glioma cells with Cisplatin (CDDP) led to a resistant phenotype. It has been demonstrated that interleukin 1 (IL-1) potentiates the cytotoxic effect of CDDP and that IL-6 decreases cytotoxicity by inhibition of apoptosis in cancer cells. Here we examined the influence of IL-
H, Poppenborg, M M, Knüpfer, H J, Galla, J E, Wolff   +3 more
openaire   +2 more sources

Mechanisms of acquired resistance to cisplatin

1994
Since the discovery of the antitumor activity in rodents of cisplatin (cis-diamminedichloroplatinum(II)) in 1968 [1], the use of this drug in treating human disease has grown to the point where it is now one of the most widely used antineoplastics. Cisplatin has an established role in the treatment of testicular, ovarian, bladder, germ cell, and head ...
openaire   +2 more sources

Tumour resistance to cisplatin: a modelling approach

Physics in Medicine and Biology, 2004
Although chemotherapy has revolutionized the treatment of haematological tumours, in many common solid tumours the success has been limited. Some of the reasons for the limitations are: the timing of drug delivery, resistance to the drug, repopulation between cycles of chemotherapy and the lack of complete understanding of the pharmacokinetics and ...
Marcu, L., Bezak, E., Olver, I., Van Doorn, T.   +3 more
openaire   +3 more sources

Overcoming cisplatin resistance in chemotherapy by biomineralization

Chemical Communications, 2013
Nano-solidified intermedias (NSI) of cisplatin were prepared via biomineralization and applied to reverse the drug resistance of cancers in vitro and in vivo by an alternative internalization pathway.
Wei, Chen, Yun, Xiao, Xueyao, Liu, Yanhong, Chen, Jiaojiao, Zhang, Xurong, Xu, Ruikang, Tang   +6 more
openaire   +2 more sources

Cellular and molecular determinants of cisplatin resistance

European Journal of Cancer, 1998
Cisplatin and carboplatin are among the most active and widely used cytotoxic anticancer drugs. However, the acquisition or presence of resistance significantly undermines the curative potential of these drugs against many malignancies. Multiple potential mechanisms of resistance have been identified at the cellular and molecular levels. Alterations in
openaire   +2 more sources

The roles of copper transporters in cisplatin resistance

Cancer and Metastasis Reviews, 2007
Platinum-based antitumor agents have been effective in the treatments of many human malignancies but the ultimate success of these agents is often compromised by development of drug resistance. One mechanism associated with resistance to platinum drugs is reduced intracellular accumulation owing to impaired drug intake, enhanced outward transport, or ...
Macus Tien, Kuo, Helen H W, Chen, Im-Sook, Song, Niramol, Savaraj, Toshihisa, Ishikawa   +4 more
openaire   +2 more sources